[go: up one dir, main page]

AR063538A1 - Tratamiento de la enfermedad de parkinson - Google Patents

Tratamiento de la enfermedad de parkinson

Info

Publication number
AR063538A1
AR063538A1 ARP070104797A ARP070104797A AR063538A1 AR 063538 A1 AR063538 A1 AR 063538A1 AR P070104797 A ARP070104797 A AR P070104797A AR P070104797 A ARP070104797 A AR P070104797A AR 063538 A1 AR063538 A1 AR 063538A1
Authority
AR
Argentina
Prior art keywords
pramipexole
parkinson
treatment
disease
active ingredient
Prior art date
Application number
ARP070104797A
Other languages
English (en)
Inventor
Jeffrey G Hurth
Elizabeth Keating
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38962581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063538(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR063538A1 publication Critical patent/AR063538A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Uso de un medicamento para el tratamiento de la enfermedad de Parkinson con el ingrediente activo seleccionado entre el grupo de pramipexol, hidrocloruro de pramipexol, dihidrocloruro de pramipexol o dihidrocloruro de pramipexol monohidrato para un medicamento para el tratamiento de la enfermedad de Parkinson en sus primeros estadios. Reivindicacion 20: Un kit de partes caracterizado porque comprende una formulacion de liberacion inmediata con un ingrediente activo seleccionado entre el grupo de pramipexol, hidrocloruro de pramipexol, dihidrocloruro de pramipexol o dihidrocloruro de pramipexol monohidrato, o cualquier otra forma de sal farmacéuticamente aceptable de pramipexol, e instrucciones de acuerdo con las cuales dicha formulacion de liberacion inmediata se tomará dos veces al día. Reivindicacion 38: Un método de mantenimiento para el tratamiento de la enfermedad de Parkinson de acuerdo con el uso descrito en cualquiera de las reivindicaciones anteriores 1 a 19.
ARP070104797A 2006-10-30 2007-10-29 Tratamiento de la enfermedad de parkinson AR063538A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86345106P 2006-10-30 2006-10-30
US86553506P 2006-11-13 2006-11-13

Publications (1)

Publication Number Publication Date
AR063538A1 true AR063538A1 (es) 2009-01-28

Family

ID=38962581

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104797A AR063538A1 (es) 2006-10-30 2007-10-29 Tratamiento de la enfermedad de parkinson

Country Status (8)

Country Link
US (1) US20100063116A1 (es)
EP (1) EP2086536A1 (es)
JP (1) JP2010508252A (es)
AR (1) AR063538A1 (es)
CA (1) CA2667924A1 (es)
CL (1) CL2007003130A1 (es)
TW (1) TW200829241A (es)
WO (1) WO2008052953A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
SE0801267A0 (sv) * 2008-05-29 2009-03-12 Cunctus Ab Metod för en användarenhet, en användarenhet och ett system innefattande nämnda användarenhet
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
TR200907554A1 (tr) 2009-10-06 2011-04-21 Sanovel İlaç San.Ve Ti̇c.A.Ş. Oral yolla dağılan pramıpexole bileşimleri.
WO2012021629A2 (en) 2010-08-11 2012-02-16 Philadelphia Health & Education Corporation Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
ES3043076T3 (en) 2013-07-12 2025-11-24 Areteia Therapeutics Inc Treating elevated levels of eosinophils and/or basophils
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
EP3062791B1 (en) 2013-10-28 2020-01-08 Drexel University Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650420A (en) * 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6156777A (en) * 1994-12-15 2000-12-05 Pharmacia & Upjohn Company Use of pramipexole as a neuroprotective agent
US20070015763A1 (en) * 2005-07-12 2007-01-18 Pfizer Inc Treatment of psychosis associated with parkinson's disease and subcortical dementias using a combination of an atypical antipsychotic with a dopamine agonist
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
JP2010525018A (ja) * 2007-04-24 2010-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物

Also Published As

Publication number Publication date
JP2010508252A (ja) 2010-03-18
EP2086536A1 (en) 2009-08-12
CL2007003130A1 (es) 2008-05-30
US20100063116A1 (en) 2010-03-11
TW200829241A (en) 2008-07-16
WO2008052953A1 (en) 2008-05-08
CA2667924A1 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
ES2376043T3 (es) Derivados de indazol para el tratamiento de enfermedades inducidas por hsp90.
AR073123A1 (es) Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica
PH12013502277A1 (en) Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids
EA201300121A1 (ru) Ингибитор дпп-4 в комбинации с дополнительным противодиабетическим агентом, таблетки, включающие указанные композиции, их применение и способ их получения
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
JP2010222367A5 (es)
BR112015029401A8 (pt) derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
ECSP10010052A (es) Formulaciones galenicas de alisquireno y valsartan
ATE529417T1 (de) 3',4',5-trimethoxyflavonderivate als die schleimsekretion stimulierendes mittel, entsprechendes verfahren und pharmazeutische zusammensetzung, die diese enthält
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
DE602007011316D1 (de) Pharmazeutische zusammensetzung mit antipsychotischer, antidepressiver oder antiepileptischer wirkung mit verringerter nebenwirkung
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
ES2582660T3 (es) Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
ECSP088285A (es) 3-(2-dimetilaminometil ciclohexil) fenol formulación retardada.
PE20030277A1 (es) Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa

Legal Events

Date Code Title Description
FB Suspension of granting procedure